Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study
Clinical Lymphoma Myeloma and Leukemia · 2024
DOI: 10.1016/j.clml.2023.09.003 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Lucio Navarro Gordan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Florida Cancer Specialists & Research Institute, Gainesville, FL, USA. Electronic address: lgordan@flcancer.com. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Multiple Myeloma. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Pharmaceuticals, Janssen Scientific Affairs LLC.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Florida Cancer Specialists & Research Institute, Gainesville, FL, USA. Electronic address: lgordan@flcancer.com.
- Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
- Samuel Oschin Cancer Center, Cedars-Sinai, Los Angeles, CA, USA.
- University of Michigan, Ann Arbor, MI, USA.
- University of Arkansas, Fayetteville, AR, USA.
- Janssen Scientific Affairs, LLC, Horsham, PA, USA.
Förderung
- Janssen Pharmaceuticals
- Janssen Scientific Affairs LLC
Zitieren
APA
Gordan, L. N., Tan, C. R., Vescio, R., Ye, J. C., Schinke, C., Medhekar, R., Fu, A. Z., Lafeuille, M. H., Thompson-Leduc, P., Khare, V., Reitan, J., Milkovich, G., Kaila, S., Davies, F., & Usmani, S. Z. (2024). Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2023.09.003
Vancouver
Gordan LN, Tan CR, Vescio R, Ye JC, Schinke C, Medhekar R, et al. Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2023.09.003
BibTeX
@article{Gordan2024,
author = {Gordan, Lucio Navarro and Tan, Carlyn Rose and Vescio, Robert and Ye, Jing Christine and Schinke, Carolina and Medhekar, Rohan and Fu, Alex Z and Lafeuille, Marie-Hélène and Thompson-Leduc, Philippe and Khare, Vipin and Reitan, John and Milkovich, Gary and Kaila, Shuchita and Davies, Faith and Usmani, Saad Z},
title = {Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2024},
doi = {10.1016/j.clml.2023.09.003}
}
EUVIMED